International Journal of Cancer Management

Published by: Kowsar

Comparison of Estrogen, Progesterone and Her2 Receptors in Primary Breast Cancer and Paired Metastatic Lymph Nodes: An Immunohistochemical Study

Azar Fani Pakdel 1 , Bahram Memar 2 , Kazem Anvari 1 , Fatemeh Homaee Shandiz 1 and Mahboobeh Sadeghi Ivari 1 , *
Authors Information
1 Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2 Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Article information
  • International Journal of Cancer Management: May 2017, 10 (5); e6634
  • Published Online: May 3, 2017
  • Article Type: Research Article
  • Received: June 11, 2016
  • Revised: July 13, 2016
  • Accepted: April 29, 2017
  • DOI: 10.5812/ijcm.6634

To Cite: Fani Pakdel A, Memar B, Anvari K, Homaee Shandiz F, Sadeghi Ivari M. Comparison of Estrogen, Progesterone and Her2 Receptors in Primary Breast Cancer and Paired Metastatic Lymph Nodes: An Immunohistochemical Study, Int J Cancer Manag. 2017 ; 10(5):e6634. doi: 10.5812/ijcm.6634.

Abstract
Copyright © 2017, International Journal of Cancer Management. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. World health organization .
  • 2. World cancer research fund .
  • 3. Chalasani P, Downey L, Stopeck AT. Caring for the breast cancer survivor: a guide for primary care physicians. Am J Med. 2010; 123(6): 489-95[DOI][PubMed]
  • 4. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010; 304(15): 1684-92[DOI][PubMed]
  • 5. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med. 2009; 360(6): 573-87[DOI][PubMed]
  • 6. Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011; 12(5): 496-503[DOI][PubMed]
  • 7. New prognostic factors for breast cancer recurrence breast cancer program. Lombardi Cancer Center.
  • 8. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004; 9(6): 606-16[DOI][PubMed]
  • 9. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998; 351(9114): 1451-67[DOI][PubMed]
  • 10. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998; 352(9132): 930-42[PubMed]
  • 11. Clark GM. Do we really need prognostic factors for breast cancer? Breast Cancer Res Treat. 1994; 30(2): 117-26[DOI][PubMed]
  • 12. Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol. 1988; 6(7): 1076-87[DOI][PubMed]
  • 13. Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1998; 52(1-3): 227-37[DOI][PubMed]
  • 14. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature. 1984; 312(5994): 513-6[DOI][PubMed]
  • 15. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785): 177-82[DOI][PubMed]
  • 16. Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SA, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 1990; 50(14): 4332-7[PubMed]
  • 17. Winstanley J, Cooke T, Murray GD, Platt-Higgins A, George WD, Holt S, et al. The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer. 1991; 63(3): 447-50[DOI][PubMed]
  • 18. Paterson MC, Dietrich KD, Danyluk J, Paterson AH, Lees AW, Jamil N, et al. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res. 1991; 51(2): 556-67[PubMed]
  • 19. Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res. 1991; 51(3): 944-8[PubMed]
  • 20. Ravdin PM, Green S, Albain KS. Initial report of the SWOG biological correlative study of c-erb-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen (T) alone. Proc Am Soc Clin Oncol . 1998; 17: 97
  • 21. McCarty KJ, Miller LS, Cox EB, Konrath J, McCarty KS. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985; 109(8): 716-21[PubMed]
  • 22. Barnes DM, Harris WH, Smith P, Millis RR, Rubens RD. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer. 1996; 74(9): 1445-51[DOI][PubMed]
  • 23. Rastelli F, Crispino S. Factors predictive of response to hormone therapy in breast cancer. Tumori. 2008; 94(3): 370-83[PubMed]
  • 24. Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer. 2000; 89(2): 111-7[DOI][PubMed]
  • 25. Rexhepaj E, Brennan DJ, Holloway P, Kay EW, McCann AH, Landberg G, et al. Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. Breast Cancer Res. 2008; 10(5)[DOI][PubMed]
  • 26. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; 17(5): 1474-81[DOI][PubMed]
  • 27. Saeedi Saedi H, Ghavam Nasiri MR, ShahidSales S, Taghizadeh A, Mohammadian N. Comparison of hormone receptor status in primary and recurrent breast cancer. Iran J Cancer Prev. 2012; 5(2): 69-73[PubMed]
  • 28. Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol. 2010; 21(6): 1254-61[DOI][PubMed]
  • 29. Nedergaard L, Haerslev T, Jacobsen GK. Immunohistochemical study of estrogen receptors in primary breast carcinomas and their lymph node metastases including comparison of two monoclonal antibodies. APMIS. 1995; 103(1): 20-4[PubMed]
  • 30. Cardoso F, Di Leo A, Larsimont D, Gancberg D, Rouas G, Dolci S, et al. Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol. 2001; 12(5): 615-20[PubMed]
  • 31. Cho EY, Han JJ, Choi YL, Kim KM, Oh YL. Comparison of Her-2, EGFR and cyclin D1 in primary breast cancer and paired metastatic lymph nodes: an immunohistochemical and chromogenic in situ hybridization study. J Korean Med Sci. 2008; 23(6): 1053-61[DOI][PubMed]
  • 32. Payne SJ, Bowen RL, Jones JL, Wells CA. Predictive markers in breast cancer--the present. Histopathology. 2008; 52(1): 82-90[DOI][PubMed]
  • 33. Tiwari DK, Tanaka S, Inouye Y, Yoshizawa K, Watanabe TM, Jin T. Synthesis and Characterization of Anti-HER2 Antibody Conjugated CdSe/CdZnS Quantum Dots for Fluorescence Imaging of Breast Cancer Cells. Sensors (Basel). 2009; 9(11): 9332-64[DOI][PubMed]
  • 34. Wu X, Liu H, Liu J, Haley KN, Treadway JA, Larson JP, et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol. 2003; 21(1): 41-6[DOI][PubMed]
  • 35. Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol. 2009; 20(9): 1499-504[DOI][PubMed]
  • 36. Elledge RM, Fuqua SA. Estrogen and progesterone receptors. 2000; : 471
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments